Are they safe? Drugs and devices receiving accelerated approval by the FDA

episode

JAMA Clinical Reviews not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

TAFS Unplugged: Iceage 14 min · 22 Sep 2026 · The Adam Friedland Show

Money, money, money 23 min · 22 Sep 2026 · The NPR Politics Podcast

Stocks Close Mixed, US Team Met with Iranians, More 6 min · 22 Sep 2026 · Bloomberg News Now

PMS 2.0 1629 - MNF Recap, Ian Rapoport, Rece Davis, Brewers Manager Pat Murphy, Davante Adams, Ole Miss Head Coach Pete Golding, Chris Gotterup, Darius Butler, & AJ Hawk 2h 43m · 22 Sep 2026 · The Pat McAfee Show

DLSS5 Explained with Linus Tech Tips 39 min · 22 Sep 2026 · The Vergecast

Ask the Mates Anything Round #2 | MOONSHOTS AMA #293 1h 26m · 22 Sep 2026 · Moonshots with Peter Diamandis

Report any issue

Source

Recorded15 Aug 2017

Publisherjamaclinicalreviews.libsyn.com ↗

Handlerec:7722888

Show notes

Some drugs and devices receive accelerated approval from the FDA in order to provide potentially important treatments for patients when effective therapies may not be available. These drugs or devices are supposed to have postmarketing studies to definitively show their efficacy or safety, but sometimes this doesn't happen. Rita F. Redberg, MD, MSc, Aaron S. Kesselheim, MD, JD, MPH, and Robert M. Califf, MD, discuss their articles characterizing studies used for the approval of high-risk medical devices and accelerated approval of drugs by the FDA. Discussed in this podcast: FDA Online

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in